Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Targeted CEA CAR-T · 4 trials · 1 indication
Adverse events and their proportion during the trial (assessed against the Common Terminology Standard for Adverse Events Version 5.0 (CTCAE 5.0) and ASTCT standards)
| Arm | Type | Description |
|---|---|---|
| Targeted CEA CAR-T intravenous infusion group | EXPERIMENTAL | - |
| Targeting CEA CAR-T pleural infusion group | EXPERIMENTAL | - |
| Targeted CEA CAR-T intravenous infusion | EXPERIMENTAL | - |
| Targeting CEA CAR-T intraperitoneal infusion group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Targeted CEA CAR-T | BIOLOGICAL | Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest |
Inclusion Criteria: \- Participants must meet all of the following criteria to be eligible for enrollment: 1. Age ≥18 years, regardless of gender. 2. Histologically or cytologically confirmed advanced, metastatic, or recurrent lung cancer, including both non-small cell lung cancer (NSCLC) and sma...
Top 20 of 76 competitors
Targeted CEA CAR-T is an investigational chimeric antigen receptor T-cell therapy being studied for the treatment of advanced lung cancer, specifically in patients whose tumors are CEA-positive. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
Targeted CEA CAR-T targets the carcinoembryonic antigen (CEA), a protein often expressed on the surface of cancer cells. The therapy is designed to direct a patient's own T cells to recognize and attack CEA-positive tumor cells in advanced lung cancer.
Targeted CEA CAR-T is being developed by Precision BioSciences, Inc., a biotechnology company whose stock trades under the ticker symbol DTIL. The company is conducting Phase 1 clinical trials for this investigational cell therapy in advanced lung cancer.
Targeted CEA CAR-T is in Phase 1 clinical development. It is an investigational therapy, meaning it has not received FDA approval and is still being evaluated for safety and efficacy in clinical trials for advanced lung cancer.
Targeted CEA CAR-T is being studied in four active Phase 1 clinical trials, all recruiting patients in China. These include NCT06992583, NCT06945523, NCT06903117, and NCT06768151, with a combined planned enrollment of 228 participants with advanced lung cancer.
Yes, Targeted CEA CAR-T is also referred to as anti-CEA CAR-T or CEA-targeting CAR-T in clinical trial titles. These names all describe the same investigational therapy that targets the CEA antigen in advanced lung cancer.